TARSUS PHARMACEUTICALS, INC. Increase (Decrease) in Contract with Customer, Asset
TARSUS PHARMACEUTICALS, INC. (TARS) reported Increase (Decrease) in Contract with Customer, Asset of $0 for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2022-05-11
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in contract with customer, asset for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in contract with customer, asset for the quarter ending 2021-03-31 was $7.20M.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in contract with customer, asset for the quarter ending 2020-03-31 was $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month |
|---|---|
| 2022-03-31 | $0.00 10-Q · filed 2022-05-11 |
| 2021-03-31 | $7.20M 10-Q · filed 2022-05-11 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |